Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors

NCT02161692 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT02161692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Phase 2
Overall status
Completed
Start date
December 31, 1996
Completion date
April 30, 2009
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumors, testicular neoplasms